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Summary
Colorectal carcinoma is the third most common cancer site in Croatia, according to the data published by the The 
Croatian National Cancer Registry. In the last decade, the knowledge about pathogenesis and molecular background of 
colorectal carcinoma has increased dramatically. More than 90% of colorectal carcinomas are adenocarcinomas originating 
from epithelial cells of the colorectal mucosa. Tumor staging is the most important prognostic predictor of clinical outcome 
for patients with colorectal carcinoma. The TNM classification has nowdays replaced other classification systems (Dukes, 
Astler-Coller) and serves as golden standard in everyday practise.In 2012, 5th Croatian Congress for Pathology resulted in 
uniform standard for pathologic reporting for all cancer sites. The future for colorectal cancer prognosis and therapy is to 
discover new molecular subtypes of colorectal cancer which represents the future of personalized oncology and will guide 
drug-development strategies.
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KOLOREKTALNI KARCINOM - PATOHISTOLO[KI STANDARDI
SA@ETAK
Prema podacima Registra za rak karcinom kolorektuma je tre}e naj~e{}e tumorsko sijelo u Hrvatskoj. U zadnjih deset 
godina imamo brojna nova saznanja o patogenezi i molekularnim karakteristikama karcinoma kolorektuma. Vi{e od 90% 
kolorektalnih karcinoma su adenokarcinomi po histolo{kom tipu, porijekla epitelnih stanica kolorektalne mukoze. Stadij 
tumora je najbitniji prognosti~ki ~imbenik za pacijente s tom bole{}u. U dana{nje je vrijeme TNM klasifikacija zamijenila 
druge klasifikacijske sustave (Dukes, Astler-Coller) i koristi se kao zlatni standard u svakodnevnoj praksi. 2012. na Hrva-
tskom kongresu patologa, doneseni su standardi za sva tumorska sjela, koje mora zadovoljavati svaki patohistolo{ki nalaz. 
Budu}nost prognoze i terapije kolorektalnog karcinoma je otkri}e novih molekularnih podtipova prema kojima bi se 
odre|ivala personalizirana onkolo{ka terapija te odredile nove strategije lije~enja.
KLJU^NE RIJE^I: karcinom kolorektuma, TNM klasifikacija, personalizirana terapija
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INTRODUCTION
Colorectal carcinoma is the third most com-
mon cancer site in Croatia, according to the data 
published by the The Croatian National Cancer 
Registry, with the 9% of incidence in men and 8% 
of incidence in women in 2013, after prostate and 
lung/bronchus cancers in men and after breast 
and lung/bronchus cancers in women. It is also 
the third leading cause of cancer-related death in 
Croatia after lung/bronchus and prostate cancers 
in men and after lung/bronchus and breast can-
cers in women in the same year (1). With the rapid 
therapeutic advancement in the era of personal-
ized medicine, the role of pathologists in the man-
agement of patients with colorectal carcinoma has 
expanded from traditional morphologists to clini-
cal consultants for gastroenterologists, colorectal 
surgeons, oncologists and medical geneticists. 
Nowdays, pathologists are not only responsible 
for providing accurate histopathologic diagnosis, 
but also for assessing pathologic staging, analyz-
ing surgical margins, searching for prognostic pa-
rameters that are not included in the staging such 
as lymphovascular and perineural invasion, and 
assessing therapeutic effect in patients who have 
received neoadjavant therapy.
In the last decade,the knowledge about patho-
genesis and molecular backgroundof colorectal 
carcinoma has increased dramatically. As a result, 
pathological diagnosis of colorectal carcinoma is 
now more complexand includes analyzing histo-
logic features of the tumours that are suggestive 
of microsatelitte instability (MSI) andselecting ap-
propriate tissue sections for MSI for identification 
of patients with increased risk for Lynch syndrome 
(2). Introduction of specific targeted therapies re-
quires implementationof results of additional mu-
tation analysis tests, such as analysis of the BRAF 
and KRAS genesmutations (3). Pathologists also 
play a central role in selecting appropriate tissue 
sections for these two mutations analysis.
HISTOPATHOLOGIC DIAGNOSIS
According to the 4th Edition of WHO Classifi-
cation of Tumours of the Digestive system, several 
histopathological variants of colorectal carcinoma 
can be distinguished (4). More than 90% of colorec-
tal carcinomas are adenocarcinomas originating 
from epithelial cells of the colorectal mucosa (5).
Other histopathological variants of colorectal car-
cinoma, some of which associaed with specific 
molecular characteristics include mucinous, sig-
net ring cell, medullary, serrated, cribriform 
 comedo-type, micropapillary, neuroendocrine, 
squamous cell, adenosquamous, spindle cell and 
undifferentiated carcinomas. Conventional ade-
nocarcinoma is characterized by glandular forma-
tion, which is the basis for histologic tumor grad-
ing. In well differentiated adenocarcinoma >95% 
of the tumor is gland forming. Moderately differ-
entiated adenocarcinoma shows 50-95% gland 
formation. Poorly differentiated adenocarcinoma 
is mostly solid with <50% gland formation. The 
terms “low-grade” and “high-grade” are nowdays 
in clinical, as well histopathologic, use due to the 
similar behaviour of well- and moderately differ-
entiated carcinomas. Morphological grading of 
tumours applies only to adenocarcinoma, ”NOS” 
(Figure 1), because other morphological variants 
carry their own prognostic significance.
Figure 1. Adenocarcinoma (“NOS”), (original magnification 
X200)
Most of colorectal carcinomas are initially di-
agnosed by endoscopic biopsy or polypectomy. 
The major aspect of microscopic examination is 
the evidence of invasion. This is very difficult in 
every day practiseespecially when the biopsy is 
superficial or poorly oriented. Material is some-
times insufficiant. If the muscularis mucosae can 
be identified, it is important to determine whether 
it is disrupted by neoplastic cells. Invasive carci-
noma invades through the muscularis mucosae at 
least into the submucosa. If carcinoma is subjected 
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to mucosa only, it is classified as carcinoma in situ. 
Another important feature of invasion is the pres-
ence of desmoplasia, a type of fibrous prolifera-
tion surrounding tumor cells.
The major difference between colorectal and 
other gastrointestinal carcinomas is the following:
in the colorectum, submucosal invasion is re-
quired for the diagnosis of a pT1 tumor and in 
other parts of the gastrointestinal tract (esopha-
gus, stomach and small intestine), mucosal inva-
sion is sufficient for the diagnosis of invasive car-
cinoma (pT1). For reasons that are not entirely 
clear but generally thought to be due to the rela-
tive paucity of lymphatics, invasion confined to 
the lamina propria and muscularis mucosae has 
no risk of nodal or distant metastasis(6). No mat-
ter what term is used by pathologists, the identifi-
cation of high grade dysplasia or intramucosal 
carcinoma in a biopsy specimen should not affect 
the decision-making for patient management. The 
decision to perform surgical resection should be 
determined by the gross appearance of the lesion, 




This special type of colorectal carcinoma is 
used if >50% of the lesionis composed of pools of 
extracellular mucin that contain malignant epithe-
lial cells, either individual or forming clusters, aci-
nar structers or layers. Tumors with a significant 
mucinous component (>10%) but <50% are cate-
gorized as adenocarcinomas with mucinous fea-
tures or mucinous differentiation. (Figure 2). The 
prognosis of mucinous adenocarcinoma in com-
parison with conventional adenocarcinoma has 
been controversial (7,8). Some of them occur in pa-
tients with hereditary nonpolyposis colorectal 
cancer (HNPCC or Lynch syndrome) and thus 
represent high-level MSI (MSI-H) tumors with ex-
pected better clinical outcome (9). In contrast, mu-
cinous adenocarcinomas that are microsatellite 
stable (MSS) are expected to behave more aggres-
sively.
Signet ring cell adenocarcinoma
Signet ring cell adenocarcinoma is rare in the 
colorectum, with frequency <1% of all colorectal 
carcinomas. It is defined by the presence of >50% 
of tumor cells with prominent intracytoplasmic 
mucin, displacing the nucleus to the periphery. 
Signet ring cells may show an infiltrative growth 
pattern or are present within the pools of extracel-
lular mucin. Most of them are poorly differentiat-
ed (high grade) and have worse outcome than 
conventional adenocarcinoma (10-12). However, 
some signet ring cell carcinomas may be MSI-H 
tumors and thus may behave as low grade tumors 
biologically (4).
Neuroendocrine carcinoma
Neuroendocrine carcinomas (NEC) are mor-
phologically similar to small cell carcinoma and 
Figure 2. Mucinous adenocarcinoma showing abundant extra-
cellular mucin (original magnification ×200)
Figure 3. Neuroendocrine carcnoma, (original magnification 
×200)
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large cell neuroendocrine carcinomas of the lung, 
they are usually found in the right colon, and are 
frequently associated with an overlying adenoma 
or adenocarcinoma, but not associated with neu-
roendocrine tumours (carcinoid tumours) (Figure 
3). Primary NECs in the colon without an associ-
ated adenoma should be distinguished from pul-
monary neuroendocrine carcinoma metastasis or 
cutaneous Merkel cell carcinoma metastasis. Ac-
cording to the cell morphology, small cell NEC 
and large cell NEC are differentiated.
Medullary carcinoma
Medullary carcinoma is extremely rare, con-
stituting approximately 5-8 cases for every 10,000 
colorectal cancers diagnosed, with a mean annual 
incidence of 3.47 (±0.75) per 10 million population 
(13). It is characterized by sheets of malignant cells 
withvesicular nuclei, prominent nucleoli, and 
abundant eosinophilic cytoplasm exhibiting pro-
minent infiltration by intraepithelial lymphocytes. 
It is strongly associated with MSI-H (14,15) and 
usually has a favorable prognosis despite its poor-
ly differentiated histology.
Colorectal adenocarcinomas are immmunohis-
tochemicaly positive for CK20 and negative for CK7. 
However, up to 20% of the tumors may exhibit 
a CK7-positive/CK20 negative or CK7-negative/
CK20-negative staining pattern. It has been suggest-
ed that reduced or absent CK20 expression in 
colorectal carcinoma is associated with MSI-H (16).
PATHOLOGIC STAGING
Tumor staging is the most important prog-
nostic predictor of clinical outcome for patients 
with colorectal carcinoma. The TNM classification 
has nowdays replaced other classification systems 
(Dukes, Astler-Coller) and serves as golden stan-
dard in everyday practise. Several modification 
systems have exchanged in the last decade. (T) de-
terminates the depth of tumor invasion; T1 (tumor 
invades submucosa), T2 (tumor invades muscula-
ris propria), T3 (tumor invades subserosa or into 
non-perinotealized pericolic or perirectal tissues) 
and T4 subcategorized as T4a (tumor penetrates to 
the surface of the visceral peritoneum) and T4b 
(tumor directly invades or is adherent to other or-
gans or structures) which can sometimes be prob-
lematic because serosal surface (visceral peritone-
um) involvement can sometimes be missed if the 
specimen is not adequately sampled for histologic 
examination or it can also be replaced with the cir-
cumferential (radial) or mesenteric margin, which 
is a nonperitonealized surface created surgically.
(N) is the extent of nodal metastasis. Accord-
ing to NCCN guidelines for treatment of cancer by 
site, AJCC and College of American Pathologists, a 
minimum of 12 lymph nodes are recommended to 
identify early-stage colorectal cancer(17-19). The 
number of lymph nodes retrieved can vary with 
age of the patient, gender, tumour grade and tu-
mour site (20). For stage II (pN0) cancer, if fewer 
than 12 lymph nodes are initially indentified, it is 
recommended that the pathologist goes back to the 
specimen and thoroughly examines tissue once 
again. If 12 lymph nodes are still not indentified, a 
comment in the report should indicate that an ex-
tensive search for lymph nodes was undertaken.
The mean number of lymph nodes retrieved 
for rectal cancers treated with neoadjuvant thera-
py is significantly less then those treated by sur-
gery alone. To date, the number of lymph nodes 
needed to accurately stage neoadjuvant-treated 
cases is unknown.
Tumour deposits (TD) are also in N category. 
They are defined as discrete foci of tumor in peri-
colorectal or mesenteryc fat away from the main 
tumor but without identifiable residual lymph 
node tissue. They should be in lymph drainage 
area. The TD’s must be mentioned (by number) in 
pathologic report and also in N1c category in case 
of T1 or T2 stage.
The prognostic significance of isolated tumor 
cells (ITCs), defined as single tumor cells or small 
clusters of tumor cells ≤0.2 mm, detected by either 
immunohistochemical staining or standard hema-
toxylin and eosin staining in regional lymph nodes 
remains unclear at present.
M0 category cannot be documented on patho-
logical evaluation, but only clinical according to 
TNM 7. M1 has been subdivided in M1a (meta stasis 
confined to one organ or site) and M1b (metastasis 
in more than one organ/site or the peritoneum).
PATHOLOGY REPORTING
In 2012, 5th Croatian Congress for Pathology 
resulted in uniform standard for pathologic re-
porting for all cancer sites.The details that should 
be included in the report for colorectal cancer are 
specimen type and size, tumor site and size, mac-
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roscopic tumor perforation, macroscopic mesorec-
tal infiltration, histologic type and grade, micro-
scopic tumor extension, margins (proximal, distal, 
radial, and lateral for nonradial transanal exci-
sion), treatment effect (for tumors treated with 
neoadjuvant therapy), lymphovascular and peri-
neural invasion, tumor deposits, TNM staging, 
total number of lymph nodes examined, size of 
lymph nodes examined and the total number of 
nodes involved, type of polyp precursor of carci-
noma (if present), assessment of histologic fea-
tures that are suggestive of MSI such as tumor-in-
filtrating lymphocytes, peritumoral Crohn-like 
lymphoid response and subtype and differentia-
tion of the tumour, k-rasgene analysis..
PROGNOSTIC FACTORS
During the last 20 years, there have been sig-
nificant advances in understanding of colorectal 
cancer pathogenesis. Different mechanisms of car-
cinogenesis underly these tumours (21). We have 
often seen that patients at the same stage of the 
disease, after radical surgery, have a completely 
different course of disease and outcome. There-
fore, we are constantly looking for new parame-
ters that will more accurately provide prognosis 
of the disease along with optimal therapy for each 
patient. It has become clear that the most accurate 
prognostic information will be achieved by com-
bining clinico-pathological and molecular data. 
Unfortunately, many patients with colorectal can-
cer receive treatment unnecessarily, because they 
would either be cured even without treatment, or 
relapse despite of the treatment.
Seven new factors have been included in the 
latest TNM staging system, none of them required 
for staging but all of them with major prognostic 
and predictive values. According to the results of 
latest researches, all of these factors are useful for 
new molecular targeted therapy and personalized 
medicine.
Tumour deposits, mentioned above are record-
ed numerically.
Circumferential resection margin (CRM) repre-
sents the adventitial soft tissue closest to the deep-
est penetration of the tumour. It is created surgi-
cally by sharp excision and it corresponds to any 
aspect of the colon that is not covered by a serosal 
layer or mesothelial cells. The serosal (peritoneal) 
surface does not constitute a surgical margin. The 
radial margins should be assessed in all colonic 
specimens with non-peritonealized surfaces. In 
transverse colon specimen which is completely 
encased with peritoneum, the mesenteric resec-
tion margin is the only relevant radial margin (22). 
On pathologic exemination it is very difficult to 
assess the demarcation between the peritoneal-
ized surface and non-peritonealized surface. 
Therefore, surgeants are highly encouraged to 
mark the area of non-peritonealized surface with a 
clip or sutture. The pathologist should measure 
the distance between the closest tumour margin 
and resection margin expressed in mm. A margin 
less than 1 mm is considered positive.
Perineural invasion must be recorded. Several 
studies have shown that the presence of perineu-
ral invasion is associated with a significantly 
worse prognosis (23-25).
Tumour regression gradeis a marker of response 
to neoadjuvat therapy. The system used to grade 
tumour response is modified from Ryan et al. (26).
0   (complete response) - no remaining viable 
tumour cells
1   (moderate response) - only small clusters 
or single cancer cells remaininig
2   (minimal response) - residual cancer re-
maining, but with predominant fibrosis
3   (poor response) - minimal or no tumour 
kill; extensive residual cancer
k-ras gene analasysdetects k-ras gene mutation 
which is associated with lack of response to treat-
ment with anti-EGFR antibody, currently recom-
mended for the patients with metastatic colorectal 
cancer.
Microsatellite instability(MSI)Hereditary non-
popyposis colorectal cancer (HNPCC), also known 
as Lynch syndrome, is a common autosomal dom-
inant syndrome characterized by early age at on-
set, nepolastic lesions, and microsatellite instabil-
ity (28). It is characterized by increased lifetime 
cancer risks primarily in the gastrointestinal and 
gynecologic tracts, with colorectal and endome-
trial carcinomas being most common.Lynch syn-
drome results from germline mutation in one of 
the four DNA mismatch repair (MMR) genes 
(MLH1, MSH2, MSH6, PMS2). Lynch syndrome 
tumours screening (immunohistochemicaly or 
MSI), according to NCCN recommendations, 
should be considered for colorectal carcinoma pa-
tients diagnosed at ≤70 years and also those older 
than 70 years who meet the Bethesda guidelines.
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CONCLUSIONS
Colorectal adenocarcinoma is a heteroge-
neous disease that involves multiple tumorigenic 
pathways. The future for colorectal cancer prog-
nosis and therapy is promising, but we must con-
centrate on optimising current methods, most of 
all histopathology and discover new molecular 
subtypes of colorectal cancer which represents the 
future of personalized oncology and will guide 
drug-development strategies.
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